APHRIA INC COM NPV (OTCMKTS:APHQF) is still climbing, even ever so slightly, after its announcement that it shipped its first cannabis to Australia’s Medlab. The Australian medical life science company is to combine the supplied cannabis extracts with its patented medicine delivery system, NanoCelle. Over a 5-day period, APHQF has added about .60 in value.
APHQF is to supply Medlab with cannabis extracts that will be used in human trials in order to test their ability to treat intractable pain in oncology patients. The company plans to manufacture up to 3,500 unit with the incoming Aphria shipments. APHQF continues to trade up as investors remain optimistic about its plan to pursue sales opportunities on the international scene. The stock is closing in on its 52-week high of $6.12 after a recent pullback. For the full year, it is up by more than 50%.
APHRIA INC COM NPV (OTCMKTS:APHQF) promulgates itself as a company that produces, supplies, and sells medical cannabis in Canada. Its cannabis products include dried flowers and cannabis oils. APHQF sells its products through its online store and telephone orders, as well as MMPR licensed producers.
According to press materials, “APHQF is one of Canada’s lowest cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada. APHQF is truly powered by sunlight, allowing for the most natural growing conditions available. We are committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders. We are the first public licensed producer to report positive cash flow from operations and the first to report positive earnings in consecutive quarters.”
Find out when $APHQF reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
“As Aphria’s first international partner, Medlab shares our vision to advance the use of medical cannabis as an alternative treatment for patients in need. We are proud to be a part of this important research, and we look forward to continuing to provide high-quality, safe and pure medical cannabis products to support Medlab’s clinical research,” said CEO Vic Neufeld.
According to the release, “the shipment is part of the previously announced agreement between Aphria and Medlab, in which Aphria will produce and supply high-yield cannabis extracts for Medlab to be used in its forthcoming human trial to test management of intractable pain in oncology patients – the first trial of its kind globally. The product formulation and permits have been approved by Health Canada and the Australian Therapeutic Goods Administration.”
Sporting a current market cap value of $829.16M, APHQF is pulling in trailing 12-month revenues of $22.2M. APHQF is far along in the cannabis sector and represents real value. Many other stocks are hypothetical in this space and pre-revenue. Obviously, that is not the case here and we will be offering updates as more information becomes available. Sign-up for continuing coverage on shares of $APHQF stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $APHQF, either long or short, and we have not been compensated for this article.